Corbus Pharmaceuticals Holdings (CRBP) Operating Expenses (2013 - 2025)

Corbus Pharmaceuticals Holdings has reported Operating Expenses for 13 years, with the latest figure at $24.4 million in Q3 2025.

• On a quarterly basis, Operating Expenses rose 57.48% year-over-year to $24.4 million in Q3 2025; TTM through Sep 2025 was $75.9 million, a 64.32% increase from a year earlier, with the FY2024 full-year figure at $48.7 million, up 8.08% from the prior year.
• Operating Expenses was $24.4 million for Q3 2025 at Corbus Pharmaceuticals Holdings, up from $19.2 million in the prior quarter.
• The five-year high for Operating Expenses was $24.4 million in Q3 2025, with the low at $8.2 million in Q3 2022.
• Average Operating Expenses over 5 years is $13.4 million, with a median of $12.3 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2025: Operating Expenses tumbled 60.31% in 2021, then soared 105.5% in 2025.
• Over 5 years, Operating Expenses stood at $10.0 million in 2021, then climbed by 7.99% to $10.8 million in 2022, then retreated by 6.42% to $10.1 million in 2023, then gained by 24.75% to $12.6 million in 2024, then jumped by 93.71% to $24.4 million in 2025.
• The last three Operating Expenses figures came in at $24.4 million (Q3 2025), $19.2 million (Q2 2025), and $19.8 million (Q1 2025), per Business Quant data.